<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although the prognostic value of p53 abnormalities in Stage III microsatellite stable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) is known, the gene expression profiles specific to the p53 status in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> background are not known </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, the current investigation has focused on identification and validation of the gene expression profiles associated with p53 mutant phenotypes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> Stage III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Genomic DNA extracted from 135 formalin-fixed paraffin-embedded tissues, was analyzed for microsatellite instability (MSI) and p53 mutations </plain></SENT>
<SENT sid="3" pm="."><plain>Further, <z:chebi fb="2" ids="33699">mRNA</z:chebi> samples extracted from five p53-mutant and five p53-<z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> snap-frozen tissues were profiled for differential gene expression by Affymetrix Human Genome U133 Plus 2.0 arrays </plain></SENT>
<SENT sid="4" pm="."><plain>Differentially expressed genes were further validated by the high-throughput quantitative nuclease protection assay (qNPA), and confirmed by quantitative real-time polymerase chain reaction (qRT-PCR) and by immunohistochemistry (IHC) </plain></SENT>
<SENT sid="5" pm="."><plain>Survival rates were estimated by Kaplan-Meier and Cox regression analyses </plain></SENT>
<SENT sid="6" pm="."><plain>A higher incidence of p53 mutations was found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> (58%) than in MSI (30%) phenotypes </plain></SENT>
<SENT sid="7" pm="."><plain>Both univariate (log-rank, P = 0.025) and multivariate (hazard ratio, 2.52; 95% confidence interval, 1.25-5.08) analyses have demonstrated that patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>-p53 mutant phenotypes had poor <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-specific survival when compared to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>-p53 <z:mp ids='MP_0002169'>wild-type</z:mp> phenotypes </plain></SENT>
<SENT sid="8" pm="."><plain>Gene expression analyses identified 84 differentially expressed genes </plain></SENT>
<SENT sid="9" pm="."><plain>Of 49 down-regulated genes, LPAR6, PDLIM3, and PLAT, and, of 35 up-regulated genes, TRIM29, FUT3, IQGAP3, and SLC6A8 were confirmed by qNPA, qRT-PCR, and IHC platforms </plain></SENT>
<SENT sid="10" pm="."><plain>p53 mutations are associated with poor survival of patients with Stage III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> and p53-mutant and <z:mp ids='MP_0002169'>wild-type</z:mp> phenotypes have distinct gene expression profiles that might be helpful in identifying aggressive subsets </plain></SENT>
</text></document>